The role of reactive oxygen species in insulin signaling in the vasculature

Antioxidants and Redox Signaling

Volumn 7, Issue 7-8, 2005, Pages 1053-1061

  Frank, Gerald D ^a   Eguchi, Satoru ^b   Motley, Evangeline D ^c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; LYSOPHOSPHATIDYLCHOLINE; MITOGEN ACTIVATED PROTEIN KINASE; MYOSIN LIGHT CHAIN; NITRIC OXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; PEROXYNITRITE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE C INHIBITOR; REACTIVE OXYGEN METABOLITE; S6 KINASE;

ANIMAL CELL; APOPTOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL GROWTH; CELL MIGRATION; CELL STRAIN 3T3; CONTROLLED STUDY; DIABETES MELLITUS; DNA SYNTHESIS; ENDOTHELIUM CELL; INFLAMMATION; INSULIN RELEASE; INSULIN RESISTANCE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; REVIEW; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANIMALS; ENDOTHELIAL CELLS; HUMANS; INSULIN; MUSCLE, SMOOTH, VASCULAR; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 22044448748     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2005.7.1053     Document Type: Review

References (99)

1. Andreozzi F, Laratta E, Sciacqua A, Perticone F, and Sesti G. Angiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser312 and Ser616 in human umbilical vein endothelial cells. Circ Res 94: 1211-1218, 2004.
2. Beckman JA, Creager MA, and Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287: 2570-2581, 2002.
3. Beckman JS and Koppenol WH. Nitric oxide, Superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 271: C1424-C1437, 1996.
4. Begum N and Ragolia L. High glucose and insulin inhibit VSMC MKP-1 expression by blocking iNOS via p38 MAPK activation. Am J Physiol Cell Physiol 278: C81-C91, 2000.
5. Begum N, Ragolia L, Rienzie J, McCarthy M, and Duddy N. Regulation of mitogen-activated protein kinase phosphatase-1 induction by insulin in vascular smooth muscle cells. Evaluation of the role of the nitric oxide signaling pathway and potential defects in hypertension. J Biol Chem 273: 25164-25170, 1998.
6. Berk BC. Redox signals that regulate the vascular response to injury. Thromb Haemost 82: 810-817, 1999.
7. Blair AS, Hajduch E, Litherland GJ, and Hundal HS. Regulation of glucose transport and glycogen synthesis in L6 muscle cells during oxidative stress. Evidence for cross-talk between the insulin and SAPK2/p38 mitogen-activated protein kinase signaling pathways. J Biol Chem 274: 36293-36299, 1999.
8. Brown EJ and Schreiber SL. A signaling pathway to translational control. Cell 86: 517-520, 1996.
9. Cruzado M, Risler N, Castro C, Ortiz A, and Ruttler ME. Proliferative effect of insulin on cultured smooth muscle cells from rat mesenteric resistance vessels. Am J Hypertens 11: 54-58, 1998.
10. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, and Lupien PJ. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334: 952-957, 1996.
11. Dimmeler S, Assmus B, Hermann C, Haendeler J, and Zeiher AM. Fluid shear stress stimulates phosphorylation of Akt in human endothelial cells: involvement in suppression of apoptosis. Circ Res 83: 334-341, 1998.
12. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, and Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399: 601-605, 1999.
13. Eguchi S, Kvasaki H, Ueno H, Frank GD, Motley ED, Eguchi K, Marumo F, Hirata Y, and Inagami T. Intracellular signaling of angiotensin 11-induced p70 S6 kinase phosphorylation at Ser(411) in vascular smooth muscle cells. Possible requirement of epidermal growth factor receptor, Ras, extracellular signal-regulated kinase, and Akt. J Biol Chem 274: 36843-36851, 1999.
14. Evans JL, Goldfine ID, Maddux BA, and Grodsky GM. Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes 52: 1-8, 2003.
15. Finkel T. Redox-dependent signal transduction. FEBS Lett 476: 52-54, 2000.
16. Folli F, Kahn CR, Hansen H, Bouchie JL, and Feener EP. Angiotensin 11 inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 100: 2158-2169, 1997.
17. Fonseca VA. Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease. Am J Cardiol 92: 50J-60J, 2003.
18. Frank GD. Activation of tyrosine kinases by reactive oxygen species in vascular smooth muscle cells: significance and involvement of EGF receptor transactivation by angiotensin II. Antioxid Redox Signal 5: 771-780, 2003.
19. Frank GD, Eguchi S, Yamakawa T, Tanaka S, Inagami T, and Motley ED. Involvement of reactive oxygen species in the activation of tyrosine kinase and extracellular signal-regulated kinase by angiotensin II. Endocrinology 141: 3120-3126, 2000.
20. Gardner CD, Eguchi S, Reynolds CM, Eguchi K, Frank GD, and Motley E D. Hydrogen peroxide inhibits insulin signaling in vascular smooth muscle cells. Exp Biol Med 228: 836-842, 2003.
21. Giasson E and Meloche S. Role of p70 S6 protein kinase in angiotensin II-induced protein synthesis in vascular smooth muscle cells. J Biol Chem 270: 5225-5231, 1995.
22. Ginsberg HN. Insulin resistance and cardiovascular disease, [see comment]. J Clin Invest 106: 453-458, 2000.
23. Gockerman A, Prevette T, Jones JI, and Clemmons DR. Insulin-like growth factor (IGF)-binding proteins inhibit the smooth muscle cell migration responses to IGF-I and IGF-II. Endocrinology 136: 4168-4173, 1995.
24. Goetze S, Kintscher U, Kawano H, Kawano Y, Wakino S, Fleck E, Hsueh WA, and Law RE. Tumor necrosis factor alpha inhibits insulin-induced mitogenic signaling in vascular smooth muscle cells. J Biol Chem 275: 18279-18283, 2000.
25. Goetze S, Blaschke F, Stawowy P, Bruemmer D, Spencer C, Graf K, Grafe M, Law RE, and Fleck E. TNFalpha inhibits insulin's antiapoptotic signaling in vascular smooth muscle cells. Biochem Biophys Res Commun 287: 662-670, 2001.
26. Griendling KK and FitzGerald GA. Oxidative stress and cardiovascular injury: Part II: animal and human studies. Circulation 108: 2034-2040, 2003.
27. Griendling KK and Ushio-Fukai M. Reactive oxygen species as mediators of angiotensin II signaling. Regul Pept 91: 21-27, 2000.
28. Griendling KK, Minieri CA, Ollerenshaw JD, and Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74: 1141-1148, 1994.
29. Griendling KK, Sorescu D, and Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 86: 494-501, 2000.
30. + pump activity. Am J Physiol 271: C2045-C2052, 1996.
31. Haffner SM, Agil A, Mykkanen L, Stern MP, and Jialal I. Plasma oxidizability in subjects with normal glucose tolerance, impaired glucose tolerance, and NIDDM. Diabetes Care 18: 646-653, 1995.
32. 2 in tumor necrosis factor alpha-mediated insulin resistance. J Biol Chem 274: 25078-25084, 1999.
33. Hattori Y, Hattori S, and Kasai K. Lipopolysaccharide activates Akt in vascular smooth muscle cells resulting in induction of inducible nitric oxide synthase through nuclear factor-kappa B activation. Eur J Pharmacol 481: 153-158, 2003.
34. Heitzer T, Schlinzig T, Krohn K, Meinertz T, and Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 104: 2673-2678, 2001.
35. Hermann C, Assmus B, Urbich C, Zeiher AM, and Dimmeler S. Insulin-mediated stimulation of protein kinase Akt: a potent survival signaling cascade for endothelial cells. Arterioscler Thromb Vasc Biol 20: 402-409, 2000.
36. Hixon ML, Muro-Cacho C, Wagner MW, Obejero-Paz C, Millie E, Fujio Y, Kureishi Y, Hassold T, Walsh K, and Gualberto A. Akt1/PKB upregulation leads to vascular smooth muscle cell hypertrophy and polyploidization. J Clin Invest 106: 1011-1020, 1011.
37. Howard G, O'Leary DH, Zaccaro D, Haffner S, Rewers M, Hamman R, Selby JV, Saad MF, Savage P, and Bergman R. Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation 93: 1809-1817, 1996.
38. Hsu YH, Chen JJ, Chang NC, Chen CH, Liu JC, Chen TH, Jeng CJ, Chao HH, and Cheng TH. Role of reactive oxygen species-sensitive extracellular signal-regulated kinase pathway in angiotensin II-induced endothelin-1 gene expression in vascular endothelial cells. J Vasc Res 41: 64-74, 2004.
39. Hsueh WA and Law RE. Insulin signaling in the arterial wall. Am J Cardiol 84: 21J-24J, 1999.
40. Hu Y, Dietrich H, Metzler B, Wick G, and Xu Q. Hyperexpression and activation of extracellular signal-regulated kinases (ERK1/2) in atherosclerotic lesions of cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol 20: 18-26, 2000.
41. 2-terminal kinase prevents neointimal formation in balloon-injured rat artery. Circ Res 88: 1120-1126, 2001.
42. Jacob A, Molkentin JD, Smolenski A, Lohmann SM, and Begum N. Insulin inhibits PDGF-directed VSMC migration via NO/cGMP increase of MKP-1 and its inactivation of MAPKs. Am J Physiol Cell Physiol 283: C704-C713, 2002.
43. Jialal I, Crettaz M, Hachiya HL, Kahn CR, Moses AC, Buzney SM, and King GL. Characterization of the receptors for insulin and the insulin-like growth factors on micro- and macrovascular tissues. Endocrinology 117: 1222-1229, 1985.
44. Jung F, Haendeler J, Goebel C, Zeiher AM, and Dimmeler S. Growth factor-induced phosphoinositide 3-OH kinase/Akt phosphorylation in smooth muscle cells: induction of cell proliferation and inhibition of cell death. Cardiovasc Res 48: 148-157, 2000.
45. Junquero DC, Schini VB, Scott-Burden T, and Vanhoutte PM. Enhanced production of nitric oxide in aortae from spontaneously hypertensive rats by interleukin-1 beta. Am J Hypertens 6: 602-610, 1993.
46. Kahn AM, Husid A, Allen JC, Seidel CL, and Song T. Insulin acutely inhibits cultured vascular smooth muscle cell contraction by a nitric oxide synthase-dependent pathway. Hypertension 30: 928-933, 1997.
47. Kahn AM, Allen JC, Seidel CL, Lichtenberg DS, Song T, and Zhang S. Insulin increases NO-stimulated guanylate cyclase activity in cultured VSMC while raising redox potential. Am J Physiol Endocrinol Metab 278: E627-E633, 2000.
48. Kahn AM, Allen JC, Seidel CL, and Zhang S. Insulin inhibits migration of vascular smooth muscle cells with inducible nitric oxide synthase. Hypertension 35: 303-306, 2000.
49. + redox state, which stimulates guanylate cyclase in vascular smooth muscle. Am J Hypertens 15: 273-279, 2002.
50. Kamata H and Hirata H. Redox regulation of cellular signalling. Cell Signal 11: 1-14, 1999.
51. Katusic ZS. Vascular endothelial dysfunction: does tetrahydrobiopterin play a role? Am J Physiol Heart Circ Physiol 281: H981-H986, 2001.
52. Kerr S, Brosnan MJ, McIntyre M, Reid JL, Dominiczak AF, and Hamilton CA. Superoxide anion production is increased in a model of genetic hypertension: role of the endothelium. Hypertension 33: 1353-1358, 1999.
53. Knebel A, Rahmsdorf HJ, Ullrich A, and Herrlich P. Dephosphorylation of receptor tyrosine kinases as target of regulation by radiation, oxidants or alkylating agents. EMBO J 15: 5314-5325, 1996.
54. 2. Proc Natl Acad Sci USA 94: 11233-11237, 1997.
55. 2-treated cells and its activation by tyrosine kinase in vitro. Proc Natl Acad Sci USA 98: 6587-6592, 2001.
56. Kuboki K, Jiang ZY, Takahara N, Ha S, Igarashi M, Yamauchi T, Feener E, Herbert T, Rhodes CJ, and King GL. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation 101: 676-681, 2000.
57. Kunsch C and Medford RM. Oxidative stress as a regulator of gene expression in the vasculature. Circ Res 85: 753-766, 1999.
58. +-pump stimulation by IGF-I in VSMC. Am J Physiol 276: H2109-H2116, 1999.
59. McFarlane SI, Kumar A, and Sowers JR. Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 91: 30H-37H, 2003.
60. Miller FJ Jr, Gutterman DD, Rios CD, Heistad DD, and Davidson BL. Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. Circ Res 82: 1298-1305, 1998.
61. 2+ but requires phosphorylation by Akt at Ser1179. J Biol Chem 276: 30392-30398, 2001.
62. Montagnani M, Ravichandran LV, Chen H, Esposito DL, and Quon MJ. Insulin receptor substrate-1 and phosphoinositide-dependent kinase-1 are required for insulin-stimulated production of nitric oxide in endothelial cells. Mol Endocrinol 16: 1931-1942, 2002.
63. Motley ED, Kabir SM, Eguchi K, Hicks AL, Gardner CD, Reynolds CM, Frank GD, and Eguchi S. Protein kinase C inhibits insulin-induced Akt activation in vascular smooth muscle cells. Cell Mol Biol (Noisy-le-grand) 47: 1059-1062, 2001.
64. Motley ED, Kabir SM, Gardner CD, Eguchi K, Frank GD, Kuroki T, Ohba M, Yamakawa T, and Eguchi S. Lysophosphatidylcholine inhibits insulin-induced Akt activation through protein kinase C-alpha in vascular smooth muscle cells. Hypertension 39: 508-512, 2002.
65. Motley ED, Eguchi K, Gardner C, Hicks AL, Reynolds CM, Frank GD, Mifune M, Ohba M, and Eguchi S. Insulin-induced Akt activation is inhibited by angiotensin II in the vasculature through protein kinase C-alpha. Hypertension 41: 775-780, 2003.
66. Nakao J, Ito H, Kanayasu T, and Murota S. Stimulatory effect of insulin on aortic smooth muscle cell migration induced by 12-L-hydroxy-5,8,10,14- eicosatetraenoic acid and its modulation by elevated extracellular glucose levels. Diabetes 34: 185-191, 1985.
67. Ohtsu H, Frank GD, Utsunomiya H, and Eguchi S. Redox-dependent protein kinase regulation by angiotensin II: mechanistic insight and its pathophysiology. Antioxid Redox Signal 2005 (in press).
68. Pandolfi A, Grilli A, Cilli C, Patruno A, Giaccari A, Di Silvestre S, De Lutiis MA, Pellegrini G, Capani F, Consoli A, and Felaco M. Phenotype modulation in cultures of vascular smooth muscle cells from diabetic rats: association with increased nitric oxide synthase expression and Superoxide anion generation. J Cell Physiol 196: 378-385, 2003.
69. Paolisso G and Giugliano D. Oxidative stress and insulin action: is there a relationship? Diabetologia 39: 357-363, 1996.
70. Pullen N and Thomas G. The modular phosphorylation and activation of p70s6k. FEBS Lett 410: 78-82, 1997.
71. Reaven GM and Chen YD. Insulin resistance, its consequences, and coronary heart disease. Must we choose one culprit? Circulation 93: 1780-1783, 1996.
72. Resnick HE, Shorr RI, Kuller L, Franse L, and Harris TB. Prevalence and clinical implications of American Diabetes Association-defined diabetes and other categories of glucose dysregulation in older adults: the health, aging and body composition study. J Clin Epidemiol 54: 869-876, 2001.
73. Romashkova JA and Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401: 86-90, 1999.
74. Rudich A, Kozlovsky N, Potashnik R, and Bashan N. Oxidant stress reduces insulin responsiveness in 3T3-L1 adipocytes. Am J Physiol 212: E935-E940, 1997.
75. Rudich A, Tirosh A, Potashnik R, Hemi R, Kanet H, and Bashan N. Prolonged oxidative stress impairs insulin-induced GLUT4 translocation in 3T3-L1 adipocytes. Diabetes 47: 1562-1569, 1998.
76. Saltiel AR. Diverse signaling pathways in the cellular actions of insulin. Am J Physiol 270: E375-E385, 1996.
77. Schini-Kerth VB and Vanhoutte PM. Nitric oxide synthases in vascular cells. Exp Physiol 80: 885-905, 1995.
78. Scott-Burden T, Elizondo E, Ge T, Boulanger CM, and Vanhoutte PM. Simultaneous activation of adenylyl cyclase and protein kinase C induces production of nitric oxide by vascular smooth muscle cells. Mol Pharmacol 46: 274-282, 1994.
79. Sowers JR. Insulin and insulin-like growth factor in normal and pathological cardiovascular physiology. Hypertension 29: 691-699, 1997.
80. Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 286: H1597-H1602, 2004.
81. Sowers JR, Epstein M, and Frohlich ED. Diabetes, hypertension, and cardiovascular diseases. Hypertension 37: 1053-1059, 2001.
82. Stabile E, Zhou YF, Saji M, Castagna M, Shou M, Kinnaird TD, Baffour R, Ringel MD, Epstein SE, and Fuchs S. Akt controls vascular smooth muscle cell proliferation in vitro and in vivo by delaying G1/S exit. Circ Res 93: 1059-1065, 2003.
83. Stout RW. Insulin as a mitogenic factor: role in the pathogenesis of cardiovascular disease. Am J Med 90: 62S-65S, 1991.
84. Takagi Y, Kashiwagi A, Tanaka Y, Maegawa H, and Shigeta Y. Insulin-specific activation of S6 kinase and its desensitization in cultured rat vascular smooth muscle cells. Atherosclerosis 113: 19-27, 1995.
85. Tiefenbacher CP. Tetrahydrobiopterin: a critical cofactor for eNOS and a strategy in the treatment of endothelial dysfunction? Am J Physiol Heart Circ Physiol 280: H2484-H2488, 2001.
86. Tirosh A, Potashnik R, Bashan N, and Rudich A. Oxidative stress disrupts insulin-induced cellular redistribution of insulin receptor substrate-1 and phosphatidylinositol 3-kinase in 3T3-L1 adipocytes. A putative cellular mechanism for impaired protein kinase B activation and GLUT4 translocation. J Biol Chem 274: 10595-10602, 1999.
87. +-ATPase gene expression by insulin in vascular smooth muscle cells. Am J Hypertens 6: 626-629, 1993.
88. Trovati M, Massucco P, Mattiello L, Costamagna C, Aldieri E, Cavalot F, Anfossi G, Bosia A, and Ghigo D. Human vascular smooth muscle cells express a constitutive nitric oxide synthase that insulin rapidly activates, thus increasing guanosine 3′:5′-cyclic monophosphate and adenosine 3′:5′-cyclic monophosphate concentrations. Diabetologia 42: 831-839, 1999.
89. Tsai EC, Hirsch IB, Brunzell JD, and Chait A. Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes 43: 1010-1014, 1994.
90. Ushio-Fukai M, Alexander RW, Akers M, Yin Q, Fujio Y, Walsh K, and Griendling KK. Reactive oxygen species mediate the activation of Akt/protein kinase B by angiotensin II in vascular smooth muscle cells. J Biol Chem 274: 22699-22704, 1999.
91. Wang CC, Gurevich I, and Draznin B. Insulin affects vascular smooth muscle cell phenotype and migration via distinct signaling pathways. Diabetes 52: 2562-2569, 2003.
92. Witztum JL. The role of oxidized LDL in atherosclerosis. Adv Exp Med Biol 285: 353-365, 1991.
93. Xi XP, Graf K, Goetze S, Hsueh WA, and Law RE. Inhibition of MAP kinase blocks insulin-mediated DNA synthesis and transcriptional activation of c-fos by Elk-1 in vascular smooth muscle cells. FEBS Lett 417: 283-286, 1997.
94. Yenush L and White MF. The IRS-signalling system during insulin and cytokine action. Bioessays 19: 491-500, 1997.
95. Yenush L, Zanella C, Uchida T, Bernal D, and White MF. The pleckstrin homology and phosphotyrosine binding domains of insulin receptor substrate 1 mediate inhibition of apoptosis by insulin. Mol Cell Biol 18: 6784-6794, 1998.
96. Zeng G and Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest 98: 894-898, 1999.
97. Zeng G, Nystrom FH, Ravichandran LV, Cong L, Kirby M, Mostowski H, and Quon MJ. Roles for insulin receptor, PI3-kinase, and Akt in insulin signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 101: 1539-1545, 2000.
98. Zhang S, Yang Y, Kone BC, Allen JC, and Kahn AM. Insulin-stimulated cyclic guanosine monophosphate inhibits vascular smooth muscle cell migration by inhibiting Ca/calmodulin-dependent protein kinase II. Circulation 107: 1539-1544, 2003.
99. Zick Y. Insulin resistance: a phosphorylation-based uncoupling of insulin signaling. Trends Cell Biol 11: 437-441, 2001.